**Trader consensus pricing "No" at 96.5% for an FDA-approved hantavirus vaccine by December 31, 2026, reflects the early preclinical or initial Phase 1 status of leading candidates.** mRNA platforms from Moderna-Korea University and UTMB, plus DNA or viral-vector approaches targeting Andes or Hantaan strains, remain far from licensure. No Phase 3 efficacy trials are underway, and full FDA approval demands completed multi-phase clinical data, manufacturing validation, and regulatory review—steps that routinely span years. Recent 2026 Andes virus clusters, including person-to-person transmission aboard the MV Hondius, have heightened attention and prompted expanded preclinical work, yet they have not compressed timelines enough to enable approval before year-end. Realistic shifts would require an unforeseen emergency-use pathway or hidden late-stage data, both improbable given current surveillance from CDC and NIAID.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गयाHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
4% संभावना
$136,375 वॉल्यूम
$136,375 वॉल्यूम
31 दिस, 2026
4% संभावना
$136,375 वॉल्यूम
$136,375 वॉल्यूम
31 दिस, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus pricing "No" at 96.5% for an FDA-approved hantavirus vaccine by December 31, 2026, reflects the early preclinical or initial Phase 1 status of leading candidates.** mRNA platforms from Moderna-Korea University and UTMB, plus DNA or viral-vector approaches targeting Andes or Hantaan strains, remain far from licensure. No Phase 3 efficacy trials are underway, and full FDA approval demands completed multi-phase clinical data, manufacturing validation, and regulatory review—steps that routinely span years. Recent 2026 Andes virus clusters, including person-to-person transmission aboard the MV Hondius, have heightened attention and prompted expanded preclinical work, yet they have not compressed timelines enough to enable approval before year-end. Realistic shifts would require an unforeseen emergency-use pathway or hidden late-stage data, both improbable given current surveillance from CDC and NIAID.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
बाज़ार खुला: May 4, 2026, 10:39 AM ET
वॉल्यूम
$136,375समाप्ति तिथि
1 जन, 2027बाज़ार खुला
May 4, 2026, 10:39 AM ETरिज़ॉल्वर
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.**Trader consensus pricing "No" at 96.5% for an FDA-approved hantavirus vaccine by December 31, 2026, reflects the early preclinical or initial Phase 1 status of leading candidates.** mRNA platforms from Moderna-Korea University and UTMB, plus DNA or viral-vector approaches targeting Andes or Hantaan strains, remain far from licensure. No Phase 3 efficacy trials are underway, and full FDA approval demands completed multi-phase clinical data, manufacturing validation, and regulatory review—steps that routinely span years. Recent 2026 Andes virus clusters, including person-to-person transmission aboard the MV Hondius, have heightened attention and prompted expanded preclinical work, yet they have not compressed timelines enough to enable approval before year-end. Realistic shifts would require an unforeseen emergency-use pathway or hidden late-stage data, both improbable given current surveillance from CDC and NIAID.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
वॉल्यूम
$136,375समाप्ति तिथि
1 जन, 2027बाज़ार खुला
May 4, 2026, 10:39 AM ETरिज़ॉल्वर
0x65070BE91...**Trader consensus pricing "No" at 96.5% for an FDA-approved hantavirus vaccine by December 31, 2026, reflects the early preclinical or initial Phase 1 status of leading candidates.** mRNA platforms from Moderna-Korea University and UTMB, plus DNA or viral-vector approaches targeting Andes or Hantaan strains, remain far from licensure. No Phase 3 efficacy trials are underway, and full FDA approval demands completed multi-phase clinical data, manufacturing validation, and regulatory review—steps that routinely span years. Recent 2026 Andes virus clusters, including person-to-person transmission aboard the MV Hondius, have heightened attention and prompted expanded preclinical work, yet they have not compressed timelines enough to enable approval before year-end. Realistic shifts would require an unforeseen emergency-use pathway or hidden late-stage data, both improbable given current surveillance from CDC and NIAID.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न